XOMA Royalty Corp. (NASDAQ: XOMA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
40.17
+0.00%
TA
Loading chart...
Snapshot
| Index | - | P/E | 24.35 | EPS (ttm) | 1.65 | Insider Own | 39.79% | Shs Outstand | 12.54M | Perf Week | 0.00% |
| Market Cap | 503.77M | Forward P/E | - | EPS next Y | -0.05 | Insider Trans | 0.00% | Shs Float | 11.97M | Perf Month | -4.11% |
| Enterprise Value | 534.04M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 7.65% | Perf Quarter | 0.43% |
| Income | 33.20M | P/S | 13.90 | EPS this Y | -49.99% | Inst Trans | - | Short Ratio | 4.10 | Perf Half Y | 52.33% |
| Sales | 36.23M | P/B | 4.23 | EPS next Y | -106.10% | ROA | 11.59% | Short Interest | 914.94K | Perf YTD | 51.07% |
| Book/sh | - | P/C | 72.02 | EPS next 5Y | 12.33% | ROE | 30.21% | 52W High | 45.22 -11.17% | Perf Year | 56.49% |
| Cash/sh | - | P/FCF | 75.94 | EPS past 3/5Y | - 13.36% | ROIC | 1.94% | 52W Low | 22.29 80.22% | Perf 3Y | 142.72% |
| Dividend Est. | - | EV/EBITDA | 10.65 | Sales past 3/5Y | 105.41% 12.39% | Gross Margin | 93.29% | Volatility | 0.00% 1.50% | Perf 5Y | 22.32% |
| Dividend TTM | - | EV/Sales | 14.74 | EPS Y/Y TTM | 195.15% | Oper. Margin | 13.73% | ATR (14) | 0.59 | Perf 10Y | 278.96% |
| Dividend Ex-Date | - | Quick Ratio | 3.59 | Sales Y/Y TTM | 25.00% | Profit Margin | 86.97% | RSI (14) | 34.34 | Recom | 2.50 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.59 | EPS Q/Q | 183.33% | SMA20 | -4.55% | Beta | 0.86 | Target Price | 44.50 |
| Payout | 17.54% | Debt/Eq | 1.10 | Sales Q/Q | -25.00% | SMA50 | -4.17% | Rel Volume | 0.00 | Prev Close | 40.17 |
| Employees | 14 | LT Debt/Eq | 1.13 | Earnings | Aug 12 | SMA200 | 18.90% | Avg Volume | 318.73K | Price | 40.17 |
| IPO Date | Jun 06, 1986 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 32.33% 0.26% | Net Debt/EBITDA | 0.60 | Volume | 0 | Change | 0.00% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-30-26 | Downgrade | HC Wainwright & Co. | Buy → Neutral | $97 → $39 |
| Feb-24-26 | Reiterated | Leerink Partners | Outperform | $45 → $50 |
| Dec-12-25 | Reiterated | Stifel Nicolaus | $50 | |
| Dec-11-25 | Reiterated | Leerink Partners | Outperform | $45 |
| Dec-11-25 | Reiterated | HC Wainwright & Co. | Buy | $97 |
| Dec-09-25 | Initiated | Lucid Capital | Buy | $76 |
| Sep-07-21 | Downgrade | Wedbush | Outperform → Neutral | |
| Sep-05-17 | Upgrade | Wedbush | Neutral → Outperform | |
| Nov-14-16 | Downgrade | Wedbush | Outperform → Neutral | |
| Jul-23-15 | Downgrade | Jefferies | Buy → Hold |
Latest News
Jul-14-26
Company
XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 35 | 52 | 28 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 3 | 3 | 0 | — | — | — | — | — | — | |
| Gross Profit | 32 | 49 | 28 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 40 | 36 | 34 | — | — | — | — | — | — | |
| Research and Development | 0 | 2 | 3 | — | — | — | — | — | — | |
| Other Operating Expense | -11 | 0 | 31 | — | — | — | — | — | — | |
| Operating Income | 6 | 11 | -40 | — | — | — | — | — | — | |
| Interest Expense | 12 | 13 | 14 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 42 | 33 | 34 | — | — | — | — | — | — | |
| Net Income Before Taxes | 33 | 32 | -19 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | -6 | — | — | — | — | — | — | |
| Consolidated Net Income | 31 | 32 | -14 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 33 | 32 | -14 | — | — | — | — | — | — | |
| Net Income | 31 | 32 | -14 | — | — | — | — | — | — | |
| EPS (Recurring) | 1.65 | 1.53 | -1.65 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 1.65 | 1.53 | -1.65 | — | — | — | — | — | — | |
| EPS (Diluted) | 1.57 | 1.46 | -1.65 | — | — | — | — | — | — | |
| EBITDA | 50 | 48 | -5 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 25.59 | 18.21 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 13.77 | 9.20 | 11.26 | — | — | — | — | — | — | |
| Gross Margin | 91.43 | 94.23 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | 17.14 | 21.15 | -142.86 | — | — | — | — | — | — | |
| Net Margin | 88.57 | 61.54 | -50.00 | — | — | — | — | — | — | |
| Shares Outstanding | 12 | 18 | 12 | — | — | — | — | — | — | |
| Market Capitalization | 482 | 479 | 315 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Trigilio Jeffrey | Chief Financial Officer | Apr 20 '26 | Option Exercise | 0.00 | 11,538 | 0 | 103,906 | Apr 22 |
| Montano Maricel Perea | Chief Legal Officer | Apr 20 '26 | Option Exercise | 0.00 | 3,370 | 0 | 41,793 | Apr 22 |
| Hughes Owen | Chief Executive Officer | Apr 20 '26 | Option Exercise | 0.00 | 10,568 | 0 | 191,264 | Apr 22 |
| Sitko Bradley | Chief Investment Officer | Apr 20 '26 | Option Exercise | 0.00 | 3,737 | 0 | 82,961 | Apr 22 |
| Trigilio Jeffrey | Chief Financial Officer | Apr 13 '26 | Option Exercise | 0.00 | 4,000 | 0 | 94,000 | Apr 15 |
| LIMBER JOSEPH M | Director | Mar 27 '26 | Option Exercise | 11.20 | 3,026 | 33,891 | 9,234 | Mar 31 |
| WYSZOMIERSKI JACK L | Director | Mar 24 '26 | Option Exercise | 11.20 | 3,026 | 33,891 | 21,530 | Mar 26 |
| Hughes Owen | Chief Executive Officer | Dec 04 '25 | Buy | 25.05 | 100,000 | 2,505,000 | 102,000 | Dec 08 |
| BURNS THOMAS M. | SVP, Finance & CFO | Sep 22 '25 | Sale | 35.99 | 4,330 | 155,820 | 30,079 | Sep 23 |
| Sitko Bradley | Chief Investment Officer | Sep 19 '25 | Option Exercise | 0.00 | 6,712 | 0 | 19,822 | Sep 23 |
| Hughes Owen | Chief Executive Officer | Sep 19 '25 | Option Exercise | 0.00 | 35,567 | 0 | 98,268 | Sep 23 |
| BURNS THOMAS M. | SVP, Finance & CFO | Sep 19 '25 | Option Exercise | 0.00 | 11,846 | 0 | 34,409 | Sep 23 |
| Montano Maricel Perea | Chief Legal Officer | Sep 19 '25 | Option Exercise | 0.00 | 3,033 | 0 | 12,134 | Sep 23 |
| Montano Maricel Perea | Chief Legal Officer | Sep 10 '25 | Option Exercise | 0.00 | 9,101 | 0 | 9,101 | Sep 12 |
| Sitko Bradley | Chief Investment Officer | Jun 30 '25 | Buy | 25.39 | 2,000 | 50,780 | 7,045 | Jul 02 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.